Patents by Inventor Kwame W. Nti-Addae

Kwame W. Nti-Addae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
    Patent number: 11466015
    Abstract: The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, depicted below as a compound of Formula (I): which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 11, 2022
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Kwame W. Nti-Addae, Leena Kumari Prasad, Thomas Storz
  • CRYSTALLINE FORMS OF AN sGC STIMULATOR
    Publication number: 20210115050
    Abstract: The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: March 7, 2019
    Publication date: April 22, 2021
    Inventors: Kwame W. Nti-Addae, Leena Kumari Prasad, Thomas Storz
  • Inhibitors of influenza viruses replication
    Patent number: 10273233
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: April 30, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Michael John Boyd, Dean Shannon, Michael Waldo, Kwame W. Nti-Addae, Yuegang Zhang
  • INHIBITORS OF INFLUENZA VIRUSES REPLICATION
    Publication number: 20180065963
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Inventors: Luc J. Farmer, Michael John Boyd, Dean Shannon, Michael Waldo, Kwame W. Nti-Addae, Yuegang Zhang
  • Inhibitors of influenza viruses replication
    Patent number: 9771361
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: September 26, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai
  • INHIBITORS OF INFLUENZA VIRUSES REPLICATION
    Publication number: 20160251353
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai